# pharma_cdmo_industry_heir Blocks 051-055 Boundary Audit

work_id: pharma_cdmo_industry_heir
range: B051-B055
scope: ARC-06 first-half material-side TR boundary audit
verdict: PASS
confidence: 96%

## Source Basis

- Phase0 ARC-06: 임상 리스크와 공급망 금융, B051-B060.
- Current wave target: B051-B055 only, one block at a time.
- Previous gate: B041-B050 audit PASS.
- Root TR: `treatments/pharma_cdmo_industry_heir_tr_block_070_draft.json`
- Current block files: `treatments/preprocess/pharma_cdmo_industry_heir/03_tr_blocks/block_051` through `block_055`

## Pass 1 - ARC Direction / Continuity

PASS.

B051-B055 cleanly pivots from consumer safety-standard licensing into clinical-risk and supply-chain finance:

- B051 turns a phase-2 clinical blank into data-room access, production-slot option, premium rider, and milestone escrow freeze rights.
- B052 turns patent collateral lending into a production-first collateral structure with know-how escrow and CMO step-in rights.
- B053 turns venture equipment distress into operating-lease priority, production slots, GMP document rights, QC equipment use, and step-in control.
- B054 turns hidden production variance into insurance premium-band adjustment, production-data feeds, accident-judgment rights, and structuring fees.
- B055 turns venture hype into disclosure veto, escrow co-signature, CMO condition strengthening, three-party pre-review, and CMO slot conversion.

Capital continuity passes:

- B051 `capital_after` equals B052 `capital_before`.
- B052 `capital_after` equals B053 `capital_before`.
- B053 `capital_after` equals B054 `capital_before`.
- B054 `capital_after` equals B055 `capital_before`.

## Pass 2 - Reward Substance / Same-Block Cider

PASS.

Each block has at least two incident beats, same-block cider, and concrete protagonist benefit.

| Block | Main Pressure | Same-Block Receipt | Concrete Gain |
| --- | --- | --- | --- |
| B051 | phase-2 success story hides clinical/production/insurance blanks | `clinical_phase2_blank_pricing_receipt` | data-room access, failure-triggered CMO slot option, insurance rider, escrow freeze |
| B052 | patent-only lending ignores production recovery | `production_first_patent_collateral_receipt` | 400억 co-arranger role, production-first collateral, know-how escrow, CMO step-in |
| B053 | venture equipment may be repossessed or used as dumb collateral | `factory_lease_production_right_receipt` | 36-month operating lease, monthly slots, GMP docs, QC equipment, operating step-in |
| B054 | insurer excludes production variance from clinical risk | `production_data_insurance_risk_receipt` | premium-band adjustment, production-data feed, accident-judgment seat, interruption rider, fee |
| B055 | venture tries overhyped clinical announcement | `venture_overheat_cmo_condition_receipt` | disclosure veto, escrow co-signature, stronger CMO terms, three-party pre-review, slot conversion |

The finance terms remain functional. Patent collateral, operating lease, insurance rider, escrow, data feed, and disclosure veto all change money, production control, or downside recovery.

## Pass 3 - Boundary / Scope / Hygiene

PASS.

- Root TR now has `_current_block_count: 55`, actual block count 55, last block `Block 55`, and `_next_block_id: Block 056`.
- B056 is not created.
- BI is not created.
- B051-B055 fixed JSON files parse successfully.
- Root TR and sequential status parse successfully.
- UTF-8 byte-level checks passed on touched JSON and audit Markdown files.
- Triple-question placeholder, replacement character, and stray question-mark hygiene checks returned zero on touched files.

## Director Decision

B051-B055 is approved as ARC-06 first-half PASS. The protagonist's power now feels sharper and more trustworthy: he stops hype, prices failure, and turns biotech risk into recoverable production, insurance, and finance rights.

## Next Unit Guidance

Next unit is B056 only. It should spend B055's 공시 사전 veto권, CMO slot 전환권, and 생산/보험/데이터 3자 사전검토권 into the IB valuation battlefield without creating BI or drafting beyond the ordered boundary.
